Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B
Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B Professional…
Cell and Gene Therapy 2025 Review: Acceleration, Accountability, and the Fight for Scalability
In 2025, Cell and Gene Therapy moved decisively from proof-of-concept to…
Lucid Diligence Brief: Neurable raises $35M Series A to scale brain-signal AI
Lucid Diligence Brief: Neurable raises $35M Series A to scale brain-signal AI…
Neuroscience 2025 Review: Disease Modification Meets Deliverability
The defining idea of 2025 was that CNS innovation became an execution…
Women’s Health 2025 Review: From Fragmented Care to Scaled Platforms
In 2025, women’s health moved decisively from niche innovation toward scaled…
Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure
The defining idea of 2025 was that incretin-era obesity care moved from “how…
Lucid Diligence Brief: Truemed $34m Series A to scale payment integration platform
Lucid Diligence Brief: Truemed $34m Series A to scale payment integration…
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal Professional…
Oncology 2025 Review: Curative-Intent Expansion, ADC Acceleration, and the Operationalization of Immunotherapy
The defining idea of 2025 was execution at scale—more patients pulled into…
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B…
Lucid Diligence Brief: Syremis Therapeutics launches with $165M Series A in schizophrenia
Lucid Diligence Brief: Syremis Therapeutics launches with $165M Series A in…
Respiratory Today—December 19, 2025
This week’s respiratory update spotlights key developments, regulatory…